SINTX Technologies, Inc. (NASDAQ: SINT) has secured purchase orders from multiple contract manufacturing customers with an aggregate value exceeding $3.2 million for the production of advanced ceramic components. The orders, sourced from several existing relationships, underscore demand for high-performance materials requiring demanding mechanical, thermal, and chemical properties. Production and shipment activities are anticipated to commence in the second half of 2026 and extend into 2027, subject to customer requirements and commercial terms.

The company’s advanced ceramic manufacturing platform supports diverse industries, leveraging expertise in silicon nitride technologies for both proprietary product development and third-party manufacturing. Eric K. Olson, Chairman and Chief Executive Officer of SINTX Technologies, highlighted that the orders reflect customer confidence in the company’s technical capabilities and manufacturing quality. He emphasized that while the long-term strategy focuses on expanding proprietary biomaterials and medical device platforms, contract manufacturing remains a key driver for revenue growth and operational leverage.

Revenue associated with these orders will be recognized in accordance with U.S. generally accepted accounting principles upon satisfaction of applicable performance obligations. The purchase orders are subject to customary customer requirements and may be modified, delayed, reduced, or cancelled based on commercial terms. SINTX Technologies is headquartered in Salt Lake City, Utah, and specializes in silicon nitride biomaterials, composites, devices, and related technologies for medical and high-value applications.

Key Details of the Purchase Orders

The company’s portfolio includes the FDA-cleared SINAPTIC Foot & Ankle Implant System for reconstructive surgery. Its business operations encompass proprietary biomaterials, medical device technologies, and contract manufacturing opportunities.